TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06319599

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Stellate ganglion block
Description: The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lidocaine hydrochloride
Description: Based on the invention above, the patients in the experimental group were provided with Stellate ganglion block , using 1.5ml of 2% Lidocaine hydrochloride (1ml: 0.5mg) and 500ug of Vitamin B12 (1ml: 0.5g). Once a day, totally 10 days.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: placebo injection
Description: The percutaneous approach via the paratracheal route was used for Stellate ganglion block. The operator stood on the side of the block, instructed the patient to lie supine with a thin pillow placed below the shoulders, and tilted the head 45° towards the blocked side, fully exposing the neck. Then, routine disinfection of the neck skin was performed. The puncture site was located 2.5 cm above the sternoclavicular joint and 1.5 cm lateral to the midline of the neck.
Study: NCT06346301

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Imagery rescripting
Description: In Imagery Rescripting participants imagine a different sequence of events based on missed emotional needs and rescript until needs are fulfilled. Duration of sessions is up to 90 minutes.
Study: NCT05112393

Intervention type: OTHER
Intervention: Development of new estimating Glomerular Filtration Rate (eGFR) equation
Description: Development Cohort:~A new estimating Glomerular Filtration Rate(eGFR) equation will be developed by using a nonlinear regression model utilizing a generalized least squares algorithm.

Intervention type: OTHER
Intervention: Validation of new estimating Glomerular Filtration Rate (eGFR) equation
Description: Validation Cohort:~Internal validation will be performed by comparing bias, precision and accuracy of the new equations and the other established equations to the measured GFR.
Study: NCT05124639

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Group self-management support program for anxiety disorders
Description: The group SMS manualized program for anxiety disorders (https://monrelief.ca) aims at improving self-management capabilities through weekly 2.5-hours sessions with 10-15 patients over a 10-week period.This trial will focus solely on the virtual format of the program. The SMS program covers the following themes: getting to know your anxiety; building self-awareness; reconsidering your lifestyle habits; adopting a problem-solving method; avoidance and exposure; acceptance and committed action; seeing things differently; managing your emotions; receiving support from others; and consolidating your toolkit.
Study: NCT05891236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAM01 1.5 mg/kg
Description: 1.5 mg/kg MAM01 will be administered via IV route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered via IV route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered via IV route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered via IV route.
Study: NCT06390280

Intervention type: PROCEDURE
Intervention: intraoperative Fraction of Inspired Oxygen
Description: Group I intraoperative Fraction of Inspired Oxygen 30%, Group II intraoperative Fraction of Inspired Oxygen 80% applied group.
Study: NCT05891236

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered via IV route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAM01 5 mg/kg
Description: 5 mg/kg MAM01 will be administered via SC route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAM01 5 mg/kg
Description: 5 mg/kg MAM01 will be administered via SC route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAM01 10 mg/kg
Description: 10 mg/kg MAM01 will be administered via IV route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAM01 40 mg/kg
Description: 40 mg/kg MAM01 will be administered via IV route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAM01 450 mg
Description: MAM01 will be administered via SC route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be administered via SC route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAM01 5 mg/kg
Description: 5 mg/kg MAM01 will be administered via IV route.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Control
Description: No drug or placebo will be administered.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAM01 600 mg
Description: MAM01 will be administered via SC route.

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: MAM01 900 mg
Description: MAM01 will be administered via SC route.
Study: NCT06416748

Intervention type: PROCEDURE
Group type: OTHER
Intervention: Minimally invasive simple hysterectomy
Description: Patients with SHAPE inclusion criteria (FIGO 2018 stage IA2 and IB1 up to 2 cm, with limited stromal invasion: \&amp;amp;lt; 10 mm on LEEP/cone and \&amp;amp;lt; 50% depth on imaging) should undergo conization with surgical margins free from invasive disease or conization with involved surgical margins followed by MRI scan or expert ultrasound scan showing no residual disease. In case of residual disease at post conization imaging still fitting inclusion criteria, another conization is recommended. After these steps minimally invasive (laparoscopy or robotic) simple hysterectomy is performed with sentinel lymph node biopsy algorithm. Adjuvant therapy is given only in case of positive surgical margins, metastatic lymph nodes, and extensive LVSI with depth of stromal infiltration over 2/3.
Study: NCT05288621

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: electroacupuncture
Description: For'four sacral points'group, Hua Tuo brand disposable acupuncture needles (size 0.40 × 100mm) and electronic needle therapy instrument SDZ-IIB will be used.Bilateral BL30 and BL35, were selected as acupoints protocol.~'Four sacral points'group consists of 8 sessions over an 4-week period after baseline(2 sessions in each week), each for 30minutes. The electroacupuncture will be set at a frequency of 2.0 Hz, continuous wave, a moderate intensity the patient can tolerate and 30 min during each treatment.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: electroacupuncture
Description: For'four sacral points'group, Hua Tuo brand disposable acupuncture needles (size 0.40 × 100mm) and electronic needle therapy instrument SDZ-IIB will be used.Bilateral BL30 and BL35, were selected as acupoints protocol.~'Four sacral points'group consists of 8 sessions over an 4-week period after baseline(2 sessions in each week), each for 30minutes. The electroacupuncture will be set at a frequency of 2.0 Hz, continuous wave, a moderate intensity the patient can tolerate and 30 min during each treatment.
Study: NCT04320940

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital Sodium Injection
Description: The initial dose will be administered intravenously over a 30-minute period. The time period between the first and second dose of phenobarbital cannot occur within 30 minutes of the end of the first dose.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Phenobarbital Sodium Injection
Description: The initial dose will be administered intravenously over a 30-minute period. The time period between the first and second dose of phenobarbital cannot occur within 30 minutes of the end of the first dose.
Study: NCT04520425

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Osteopathic manipulative therapy
Description: 1. Mandibular: the clinician applies gentle pressure bilaterally to the subject's mandible, in the direction of the patient's clavicles.~2. Frontal: the clinician applies gentle pressure bilaterally to the subject's forehead, in a direction halfway between the parietals and ears.~3. Temporal: the clinician applies gentle pressure bilaterally to the subject's temples, in the direction of the patient's occiput.~4. Parietal: the clinician applies gentle pressure bilaterally to the subject's parietal bones, in the direction of the patient's occipital atlanto joint.~5. Occipital: the clinician applies gentle pressure to the subject's occipital bone, in the direction of the patient's neck.
Study: NCT05581212

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Tuberculosis Case-Finding, Treatment and Prevention Public Health Pack
Description: Combined active case-finding, treatment and prevention of TB amongst HH contacts of TB cases, associated with initiation of standard of care (SOC) treatment in active TB cases and initiation of TB preventive therapy in those contacts without active TB, based on free screening. This intervention will be compared to the standard of care available in the country.
Study: NCT05894850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through by telephone .
Description: An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients by telephone.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through message.
Description: An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients through message.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds the patients through message.
Description: An automatic surveillance (AS) system to accurately identify post-polypectomy patients, assign surveillance intervals for different risks of patients and proactively follow up with patients at certain times. AI based automatic surveillance (AS) system (ENDOANGEL-AS) reminds patients through message.
Study: NCT06537973

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: İndividualized care education
Description: A single session of training will be given to the mothers in the experimental group. In addition, the mother will be provided with counseling by the researcher at any time she wishes. The aim is to increase the mother-infant bonding levels and self-efficacy of the mothers, who will be supported by the care plans that will be created based on Swanson\&#39;s Theory of Care, and to adapt more easily to the role of motherhood, by evaluating them with the help of check-lists after the observations.
Study: NCT05894850

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Manually remind the patients
Description: Medical staff remind patients manually .
Study: NCT05408663

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: EXT608
Description: EXT608 is an investigational drug administered via subcutaneous injection

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: matching placebo administered via subcutaneous injection
Study: NCT05321303

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Serious Game
Description: Each participant of the Serious game group played 1 scenario of MetaHospital, a screen-based simulation on the management of diabetic ketoacidosis. Immediately after the serious game was played, 5 open-ended questionnaires were sent to the students to evaluate the game usability.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Standard Patients
Description: Each participant of the standardized patient's group played 1 scenario on the management of diabetic ketoacidosis and then a 30-minute analysis session with the trainer joined.
Study: NCT05444309

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Quadratus lumborum (QL) block group
Description: patient will receive 0.5 mg/kg of bupivacaine 0.25% through the quadratus lumborum block approach

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Pericapsular Nerve Group (PENG) block group
Description: patient will receive 0.5 mg/kg of bupivacaine 0.25% through the Pericapsular Nerve Group (PENG) block
Study: NCT06265376

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Educational Video
Description: A recorded educational video will be presented to the patient prior to meeting with the provider at the presurgical meeting
Study: NCT05857163

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rifasutenizol placebo capsules
Description: BID
Study: NCT04975646

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prescribed exercise program
Description: Active or passive exercises for the spastic upper limb, including functional electrical stimulation (FES), performed regularly for two weeks.
Study: NCT05114603

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX208
Description: level 1:600mg po Bid level 2:900mg po Bid

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HLX208
Description: level 1:600mg po Bid level 2:900mg po Bid
Study: NCT06108934

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Hip stem prosthesis
Description: The Insignia hip stem prosthesis will be used in cementless total hip replacement surgery (THA). The surgery typically takes approximately two hours. All study participants will receive the Insignia hip stem and compatible components. Experienced Orthopaedic Surgeons trained in THA will perform the surgeries as per the standard surgical technique guide for this prosthesis.
Study: NCT05593224

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intracranial Stent (Tonbridge)
Description: The intracranial stent consists of a self-expanding, laser-carved nickel-titanium stent and its delivery system.
Study: NCT06251713

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VeXUS score guided fluid management strategy
Description: During the first 3 postoperative days, the VeXUS score is estimated daily by ultrasound. If VeXUS score \>1, diuretic-induced fluid removal will be administred (target diuresis: 2-4mL/kg/h). The diuretic administration protocol is derived from the CARRESS HF study: bolus followed by a continuous administration of Furosemide with thiazide added based on preoperative diuretic administration status.~To prevent hypokalaemia and dysnatremia, a protocol for potassium supplementation and intravenous administration of chloride serum or hypotonic perfusion is planned.~Fluid removal will be suspended if severe metabolic disturbance (pH\>7.55 with HCO3-\>40mmol/L or serum K+ \<3 mmol/L or serum Na\>150 mmol/L) or haemodynamic instability (hypoperfusion) with fluid responsiveness occurs. Regardless of the VeXUS score, diuretics will be introduced in case of pulmonary oedema.~Haemodynamic status will be every 12 hours to detect side effects attributable to diuretic-induced fluid removal.

Intervention type: OTHER
Group type: OTHER
Intervention: Usual care
Description: Fluid management will be at the discretion of attending physician, who will be blinded to the patient's VeXUS score status.
Study: NCT03762603

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Robotic exoskeleton device
Description: It is a non invasive and non significant risk medical device which wraps around operated knee to support motion.
Study: NCT06539468

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Best Practice
Description: Receive SOC treatment

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Educational Activity
Description: Watch an educational video on AS for LR-BCC

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Patient Observation
Description: Undergo active surveillance

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Survey Administration
Description: Ancillary studies
Study: NCT06049758

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (intervention)
Description: Patients with right-side colon cancer (caecum, ascending, or hepatic flexure); were diagnosed by CT entero-colonography, colonoscopy, and biopsy who undergo laparoscopic right hemicolectomy

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 Mg/0.4 mL Injectable Solution
Description: Enoxaparin sodium 40 mg subcutaneous injection will be administered 12 hours before the operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Enoxaparin 40 Mg/0.4 mL Injectable Solution
Description: Enoxaparin sodium 40 mg subcutaneous injection will be administered 12 hours before the operation

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500mg
Description: Levofloxacin 500 mg intravenous injection will be administered 1 hour before the operation.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Levofloxacin 500mg
Description: Levofloxacin 500 mg intravenous injection will be administered 1 hour before the operation.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: LAPAROSCOPIC RIGHT HEMICOLECTOMY procedure (Conventional)
Description: Patients with right-side colon cancer (caecum, ascending, or hepatic flexure); were diagnosed by CT entero-colonography, colonoscopy, and biopsy who undergo laparoscopic right hemicolectomy
Study: NCT06139913

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: aerobic exercise
Description: moderate intensity aerobic exercise using treadmill
Study: NCT05689840

Intervention type: PROCEDURE
Intervention: Receiving inpatient surgical intervention
Description: Receiving inpatient surgical intervention in Peking Union Medical College Hospital

Intervention type: PROCEDURE
Intervention: Receiving inpatient surgical intervention
Description: Receiving inpatient surgical intervention in Peking Union Medical College Hospital

Intervention type: PROCEDURE
Intervention: Receiving inpatient surgical intervention
Description: Receiving inpatient surgical intervention in Peking Union Medical College Hospital

Intervention type: PROCEDURE
Intervention: Receiving inpatient surgical intervention
Description: Receiving inpatient surgical intervention in Peking Union Medical College Hospital

Intervention type: PROCEDURE
Intervention: Receiving inpatient surgical intervention
Description: Receiving inpatient surgical intervention in Peking Union Medical College Hospital

Intervention type: PROCEDURE
Intervention: Receiving inpatient surgical intervention
Description: Receiving inpatient surgical intervention in Peking Union Medical College Hospital

Intervention type: PROCEDURE
Intervention: Receiving inpatient surgical intervention
Description: Receiving inpatient surgical intervention in Peking Union Medical College Hospital
Study: NCT05473533

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo; formulated as solution for inhalation without active substance.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PRS-220
Description: PRS-220; formulated as solution for inhalation.
Study: NCT06402188

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ColoSeal ICD Device
Description: The subject will undergo scheduled resection per the surgeon's preferred technique. Following completion of the anastomosis, the Intraluminal Colonic Diversion (ICD) Device will be inserted, advanced and positioned with the ICD Delivery System transanally. The ICD Device will remain in place for 10± 2 days. Anastomotic leak testing will be performed prior to scheduled removal.
Study: NCT06224530

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Single dose of 500mg levetiracetam The capsules of levetiracetam and placebo will be visibly the same.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levetiracetam
Description: Single dose of 500mg levetiracetam The capsules of levetiracetam and placebo will be visibly the same.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of 75mg ascorbic acid. The capsules of levetiracetam and placebo will be visibly the same.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Single dose of 75mg ascorbic acid. The capsules of levetiracetam and placebo will be visibly the same.
Study: NCT05402943

Intervention type: BEHAVIORAL
Intervention: Nursing Care Program for Endometriosis
Description: Nursing Care Program for Endometriosis, developed in line with Health Promotion Model

Intervention type: BEHAVIORAL
Intervention: EHP-5 Endometriosis Health Promotion Model.
Description: EHP-5 Endometriosis Health Promotion Model. A questionnaire used to measure the quality of life of women with endometriosis

Intervention type: BEHAVIORAL
Intervention: EHP-5 Endometriosis Health Promotion Model.
Description: EHP-5 Endometriosis Health Promotion Model. A questionnaire used to measure the quality of life of women with endometriosis

Intervention type: BEHAVIORAL
Intervention: Healthy Life Style Behaviours Scale II.
Description: A questionnaire used to measure the Healthy Life Style Behaviours.

Intervention type: BEHAVIORAL
Intervention: Healthy Life Style Behaviours Scale II.
Description: A questionnaire used to measure the Healthy Life Style Behaviours.

Intervention type: BEHAVIORAL
Intervention: The Satisfaction Questionnaire for Nursing Care Program for women with Endometriosis.
Description: A questionnaire used to measure the satisfaction levels of women with endometriosis who applied the Nursing Care Program for women with endometriosis.
Study: NCT04702373

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: passive range of motion exercise therapy
Description: Systematic flexion-extension with gentle compression at the end of the movement is performed 10 times at the wrist, elbow, shoulder, ankle, knee, and hip joints. Ten repetitions of adduction-abduction are performed at the shoulder and hip joints.
Study: NCT03892980

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Nipple-Sparing Mastectomy
Description: Nipple-sparing mastectomy using da Vinci Surgical Systems.